Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

Reply to Frange and Leruez-Ville, “Caution Is Required before Recommending Wide Use of Letermovir as Salvage Therapy for Cytomegalovirus Diseases”

Nicholas A. Turner, Cameron R. Wolfe
Nicholas A. Turner
Duke University School of Medicine, Division of Infectious Diseases, Durham, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cameron R. Wolfe
Duke University School of Medicine, Division of Infectious Diseases, Durham, North Carolina, USADuke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00453-19
  • Article
  • Info & Metrics
  • PDF
Loading

REPLY

We thank Dr. Frange and Dr. Leruez-Ville for their comments regarding our recent article (1).

First, due to the inherent limitations of a case series, we agree that it is impossible to rule out potential confounding benefits from concurrent intravitreal treatments. While such confounding cannot be eliminated, the cases of successful CMV retinitis treatment with intravitreal dosing cited by Frange and Leruez-Ville involved either continuous delivery via ganciclovir implant or more than 4 serial injections (2–4). None of our patients received any drug-delivery implants (which are not currently available in the United States) and only one (patient D) received a comparable regimen to that described by Fan et al. (4). As presented in Fig. 1 of our recent article (1), patient A received just a single intravitreal foscarnet dose; patient C received none; and patient D received 3 total injections—fewer doses than described in prior case reports of successful treatment by intravitreal therapies alone.

Second, Frange and Leruez-Ville emphasize the important fact that viral subpopulations may have different susceptibilities. The possibility exists that wild-type virus was present within the retinas of our patients, while resistant virus was isolated from blood. We confirmed this finding in one patient (patient B), in whom CMV resistance testing of aqueous fluid was performed. In this case, no UL97 or UL54 resistance mutations were identified in aqueous fluid, sent for testing prior to initiation of letermovir therapy. The potential for compartmentalization will be an important consideration for larger studies.

Third, this case series was not designed to assess the mechanisms by which letermovir resistance emerged. We cited the prior in vitro work by Chou et al. suggesting that mutations conferring letermovir resistance appear rapidly in culture and agree that this mechanism is most likely (5). At the same time, since we did not conduct deep sequencing of viral isolates before and after receipt of letermovir, we could not make definitive conclusions about the manner by which letermovir resistance arose. As such, we felt it was prudent to present the potential for resistant CMV subpopulations as an alternative mechanism.

Overall, we are in agreement that caution is warranted with use of letermovir for therapeutic rather than prophylactic or suppressive purposes. We are hopeful that future research will better address some of the interesting and important questions raised here.

FOOTNOTES

  • This is a response to a letter by Frange and Leruez-Ville (https://doi.org/10.1128/AAC.00178-19).

  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Turner N,
    2. Strand A,
    3. Grewal DS,
    4. Cox G,
    5. Arif S,
    6. Baker AW,
    7. Maziarz EK,
    8. Saullo JH,
    9. Wolfe CR
    . 2019. Use of letermovir as salvage therapy for drug-resistant CMV retinitis: a case series. Antimicrob Agents Chemother 63:e02337-18. doi:10.1128/AAC.02337-18.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Kuo IC,
    2. Imai Y,
    3. Shum C,
    4. Martin DF,
    5. Kuppermann BD,
    6. Margolis TP
    . 2003. Genotypic analysis of cytomegalovirus retinitis poorly responsive to intravenous ganciclovir but responsive to the ganciclovir implant. Am J Ophthalmol 135:20–25. doi:10.1016/S0002-9394(02)01758-0.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Bakshi NK,
    2. Fahle GA,
    3. Sereti I,
    4. Wiley H,
    5. Nussenblatt RB,
    6. Sen HN
    . 2012. Cytomegalovirus retinitis successfully treated with ganciclovir implant in a patient with blood ganciclovir resistance and ocular ganciclovir sensitivity. Eye (Lond) 26:759–760. doi:10.1038/eye.2012.17.
    OpenUrlCrossRef
  4. 4.↵
    1. Fan JJ,
    2. Tao Y,
    3. Hwang DK
    . 2018. Comparison of intravitreal ganciclovir monotherapy and combination with foscarnet as initial therapy for cytomegalovirus retinitis. Int J Ophthalmol 11:1638–1642. doi:10.18240/ijo.2018.10.10.
    OpenUrlCrossRef
  5. 5.↵
    1. Chou S
    . 2015. Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance. Antimicrob Agents Chemother 59:6588–6593. doi:10.1128/AAC.01623-15.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
Reply to Frange and Leruez-Ville, “Caution Is Required before Recommending Wide Use of Letermovir as Salvage Therapy for Cytomegalovirus Diseases”
Nicholas A. Turner, Cameron R. Wolfe
Antimicrobial Agents and Chemotherapy Apr 2019, 63 (5) e00453-19; DOI: 10.1128/AAC.00453-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Reply to Frange and Leruez-Ville, “Caution Is Required before Recommending Wide Use of Letermovir as Salvage Therapy for Cytomegalovirus Diseases”
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
Share
Reply to Frange and Leruez-Ville, “Caution Is Required before Recommending Wide Use of Letermovir as Salvage Therapy for Cytomegalovirus Diseases”
Nicholas A. Turner, Cameron R. Wolfe
Antimicrobial Agents and Chemotherapy Apr 2019, 63 (5) e00453-19; DOI: 10.1128/AAC.00453-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • REPLY
    • FOOTNOTES
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2019 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596